Julia Katharina Schwarze

Author

Universitair Ziekenhuis Brussel ORCID

Also Known As

J Schwarze, J.K. Schwarze, Julia K Schwarze, Julia K. Schwarze, Julia Katharina Schwarze, Julia Schwarze

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Universitair Ziekenhuis Brussel Vrije Universiteit Brussel Université Libre de Bruxelles Centre Hospitalier Universitaire Brugmann Université Paris Cité

About

Julia Katharina Schwarze is an author at Universitair Ziekenhuis Brussel specializing in medicine, radiation oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	116
2	Health Sciences	1	1	11
3	Allergy	1	1	22
4	Cell Biology	1	1	37
5	Cellular Physiology	1	1	37

Julia Katharina Schwarze

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Acute Cerebrovascular Disease in the Young Arndt Rolfs, Franz Fazekas, Ulrike Grittner, Stroke	2013	210
Therapeutic depletion of CCR8<sup>+</sup> tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy Helena Van Damme, Bruno Dombrecht, Máté Kiss, Journal for ImmunoTherapy of Cancer	2021	192
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy Teofila Seremet, Yanina Jansen, Simon Planken, Journal of Translational Medicine	2019	116
Safety and clinical impact of FEES – results of the FEES-registry Rainer Dziewas, M. auf dem Brinke, Ulrich Birkmann, Neurological Research and Practice	2019	111
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Journal for ImmunoTherapy of Cancer	2021	101
<i>Ex vivo</i>generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer Inès Dufait, Julia Katharina Schwarze, Thérèse Liechtenstein, Oncotarget	2015	73
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma Prachi Bhave, Tasnia Ahmed, Serigne Lo, Journal for ImmunoTherapy of Cancer	2022	59
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx) Gil Awada, Laïla Ben Salama, Jennifer Cremer, Journal for ImmunoTherapy of Cancer	2020	54
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using<i>ex vivo</i>myeloid-derived suppressor cells as a readout of therapeutic efficacy Thérèse Liechtenstein, Noemí Pérez‐Janices, Idoia Blanco‐Luquin, OncoImmunology	2014	43
Neurocognitive Function, Psychosocial Outcome, and Health‐Related Quality of Life of the First‐Generation Metastatic Melanoma Survivors Treated with Ipilimumab Anne Rogiers, Christophe Leys, Justine Lauwyck, Journal of Immunology Research	2020	39

Page 1